drugset / Trial / NCT03539055

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

NCT03539055

NaSingle-groupOpen-labelPrevention

Summary

Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.) to prevent device related thrombus.

Timeline

Start
2018-09-01
Primary completion
2023-12-31
Completion
2024-02-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 75 mg Oral
Subject Dabigatran etexilate Unknown 150 mg Oral